Consensus interferon for earlier non-responder or relapser patients with chronic hepatitis C.

被引：0
|
作者：
Karasu, Z [1 ]
Gurakar, A [1 ]
Jazzar, A [1 ]
Emmett, C [1 ]
Hulagu, S [1 ]
Wright, H [1 ]
机构：
[1] Baptist Med Ctr, Oklahoma Transplantat Inst, Oklahoma City, OK 73112 USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1874
引用
收藏
页码：629A / 629A
页数：1
相关论文
共 50 条
  • [21] GGT/ALT ratio is related to serum markers of fibrosis and predict sustained response to interferon (IFN) plus ribavirin (RBV) in non-responder/relapser patients with chronic hepatitis (CHC)
    Moreno-Monteagudo, JA
    Majano, P
    Borque, MJ
    Garcia-Buey, L
    Garcia-Monzon, C
    Moreno-Otero, R
    JOURNAL OF HEPATOLOGY, 2001, 34 : 125 - 126
  • [22] Interferon alpha plus ribavirin tor chronic hepatitis C genotype 1b non-responder patients to interferon alone.
    Iacono, OL
    Castro, A
    Diago, M
    Cors, R
    Borque, MJ
    Buey, LG
    Monzon, CG
    Pedreira, J
    Otero, RM
    HEPATOLOGY, 1999, 30 (04) : 266A - 266A
  • [23] Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Puig-Basagoiti, F
    Forns, X
    Furcic, I
    Ampurdanés, S
    Giménez-Barcons, M
    Franco, S
    Sanchez-Tapias, JM
    Saiz, JC
    JOURNAL OF GENERAL VIROLOGY, 2005, 86 : 1067 - 1075
  • [24] Induction therapy with consensus interferon in the treatment of patients with chronic hepatitis C.
    Kwo, PY
    Fields, S
    Chalasani, N
    Cho, W
    Crabb, DW
    Cummings, OW
    Imperiale, TF
    Lumeng, L
    McGill, JM
    Ness, RM
    Pintozzi, R
    Jones, B
    Lansford, C
    Maier, J
    Isenberg, M
    Mark, D
    Bennet, C
    Noar, M
    McCone, J
    Chasen, R
    Geissinger, B
    Goldstein, M
    Thuluvath, P
    GASTROENTEROLOGY, 2000, 118 (04) : A1460 - A1460
  • [25] Evaluation of initial biochemical and virological responses to induction therapy with interferon-A2B in combination with ribavirin and ketoprofen for non-responder patients with chronic hepatitis C.
    Munoz, AE
    Levi, D
    Miguez, C
    Cisterna, D
    Terg, R
    HEPATOLOGY, 2000, 32 (04) : 554A - 554A
  • [26] Chronic hepatitis C treatment guidelines need revision: A case of hepatitis C non-responder
    Khan, Mahboob A.
    Somers, William R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S386 - S387
  • [27] Amantadine plus interferon is not effective in non responder to interferon chronic hepatitis C patients.
    Diago, M
    Perez-Anton, C
    García, V
    Carbonell, P
    Cors, R
    Aznar, V
    Martinez, M
    Andreu, J
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [28] The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-α and ribavirin combined therapy for chronic hepatitis C patients
    Chen, P. -J.
    Hwang, Y.
    Lin, C. G. -J.
    Wu, Y. -J.
    Wu, L. S. -H.
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2008, 35 (02) : 153 - 157
  • [29] Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C
    Caballero, T
    Pérez-Milena, A
    Masseroli, M
    O'Valle, F
    Salmerón, FJ
    Del Moral, RMG
    Sánchez-Salgado, G
    JOURNAL OF HEPATOLOGY, 2001, 34 (05) : 740 - 747
  • [30] Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient
    Emara, Mohamed H.
    Radwan, Mohamed I.
    VIROLOGY JOURNAL, 2011, 8
12345